Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nowo zdiagnozowany rak wątroby, trzustki, żółci, przełyku, jelita grubego lub płuc
- •Przerzuty raka do wątroby z innego źródła
- •Wiek 18 lat i więcej
✗ Disqualifies
- •Poniżej 18 lat
- •Osoby pozbawione wolności
- •Niemożliwość udzielenia świadomej zgody
- •Ciąża
- •Pilna lub nagła operacja w momencie diagnozy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- August 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
University of Colorado Denver
Aurora, United States
UCHealth Highlands Ranch Hospital
Highlands Ranch, United States
Trial contact
Tracey MacDermott, BA BS CCRC
Ivan Rodriguez, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/25/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.